Pfizer’s COVID‑19 Pill Gets the Green Light in the US
Yesterday, the U.S. government gave the OK to Paxlovid, Pfizer’s much‑anticipated antiviral pill. It’s now available for anyone 12 and older who’s at risk of a serious bout with the virus. The news comes hot on the heels of the Omicron surge that’s been sweeping the country.
Why Paxlovid is a Game‑Changer
In clinical trials, Paxlovid cut hospital visits and deaths by almost 90 % among people who were likely to get seriously ill. Labs also suggest the drug still holds up against Omicron, the stealthy strain that’s made the others in the fight look like old‑fashioned tools.
Production & Supply Status
- Pfizer boosted its 2022 outlook from 80 million to 120 million treatment courses.
- The company can ship 180 000 courses this year.
- White House guide Jeff Zients said 265 000 courses will be ready by January, with the supply growing month by month.
- Govt. orders: 10 million courses—$530 each—are expected within six months.
Expert Take
Amesh Adalja from Johns Hopkins calls the approval a big win and a step toward treating COVID‑19 like any other illness. He warns two things: scarcity in the short term and the need for quick diagnosis—something still tricky with the testing hiccups we’ve been juggling.
What Makes the Pill Different
- Paxlovid combines a new drug with ritonavir, an older antiviral.
- Both medications stay in your bloodstream for about 12 hours, and you take them for five days straight.
- Ritonavir can bump up the effects of other prescriptions, but most folks can adjust their meds safely.
- The pill is a lot cheaper and easier to get than the monoclonal antibody therapies that usually need an IV in a hospital.
How It Fits Into the Bigger Picture
Omicron now accounts for over 70 % of new cases in the U.S., with past infection or vaccines offering only partial protection. A booster shot does boost that shield a bit.
While the trials didn’t test people under 18, Pfizer says the adult dose should give kids 12 and older the same drug exposure—provided they weigh at least 40 kg (about 88 lb).
Future Plans
- Paxlovid is only prescription‑only and should start ASAP after a COVID‑19 diagnosis, ideally within five days of symptoms.
- Pfizer plans to file for full approval next year.
- It’s opening doors for generic versions in 95 low‑ and middle‑income countries through the Medicines Patent Pool.
What’s Happening Else
Merck’s molnupiravir is also under review, offering a 30 % reduction in hospitalisation risk in trials.
Market Reaction
Pfizer shares ticked up slightly—1 %—to $59.45 on the trading day.
